Clinical outcomes and survival in AA amyloidosis patients

Detalhes bibliográficos
Autor(a) principal: Ayar,Yavuz
Data de Publicação: 2017
Outros Autores: Ersoy,Alparslan, Oksuz,Mustafa Ferhat, Ocakoglu,Gokhan, Vuruskan,Berna Aytac, Yildiz,Abdülmecit, Isiktas,Emel, Oruc,Aysegül, Celikci,Sedat, Arslan,Ismail, Sahin,Ahmet Bilgehan, Güllülü,Mustafa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Reumatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600535
Resumo: Abstract Aim Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. Methods: A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Results: Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65 ± 3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p = 0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p = 0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p = 0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3 ± 16 months. Conclusion Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.
id SBR-1_fa8fd71a4b08ca3bc68a82fbff7d7f63
oai_identifier_str oai:scielo:S0482-50042017000600535
network_acronym_str SBR-1
network_name_str Revista Brasileira de Reumatologia (Online)
repository_id_str
spelling Clinical outcomes and survival in AA amyloidosis patientsAA amyloidosisChronic kidney diseaseFamilial Mediterranean feverMortalityRenal survivalAbstract Aim Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. Methods: A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Results: Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65 ± 3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p = 0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p = 0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p = 0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3 ± 16 months. Conclusion Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.Sociedade Brasileira de Reumatologia2017-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600535Revista Brasileira de Reumatologia v.57 n.6 2017reponame:Revista Brasileira de Reumatologia (Online)instname:Sociedade Brasileira de Reumatologia (SBR)instacron:SBR10.1016/j.rbre.2017.02.002info:eu-repo/semantics/openAccessAyar,YavuzErsoy,AlparslanOksuz,Mustafa FerhatOcakoglu,GokhanVuruskan,Berna AytacYildiz,AbdülmecitIsiktas,EmelOruc,AysegülCelikci,SedatArslan,IsmailSahin,Ahmet BilgehanGüllülü,Mustafaeng2017-12-08T00:00:00Zoai:scielo:S0482-50042017000600535Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0482-5004&lng=pt&nrm=isoONGhttps://old.scielo.br/oai/scielo-oai.php||sbre@terra.com.br1809-45700482-5004opendoar:2017-12-08T00:00Revista Brasileira de Reumatologia (Online) - Sociedade Brasileira de Reumatologia (SBR)false
dc.title.none.fl_str_mv Clinical outcomes and survival in AA amyloidosis patients
title Clinical outcomes and survival in AA amyloidosis patients
spellingShingle Clinical outcomes and survival in AA amyloidosis patients
Ayar,Yavuz
AA amyloidosis
Chronic kidney disease
Familial Mediterranean fever
Mortality
Renal survival
title_short Clinical outcomes and survival in AA amyloidosis patients
title_full Clinical outcomes and survival in AA amyloidosis patients
title_fullStr Clinical outcomes and survival in AA amyloidosis patients
title_full_unstemmed Clinical outcomes and survival in AA amyloidosis patients
title_sort Clinical outcomes and survival in AA amyloidosis patients
author Ayar,Yavuz
author_facet Ayar,Yavuz
Ersoy,Alparslan
Oksuz,Mustafa Ferhat
Ocakoglu,Gokhan
Vuruskan,Berna Aytac
Yildiz,Abdülmecit
Isiktas,Emel
Oruc,Aysegül
Celikci,Sedat
Arslan,Ismail
Sahin,Ahmet Bilgehan
Güllülü,Mustafa
author_role author
author2 Ersoy,Alparslan
Oksuz,Mustafa Ferhat
Ocakoglu,Gokhan
Vuruskan,Berna Aytac
Yildiz,Abdülmecit
Isiktas,Emel
Oruc,Aysegül
Celikci,Sedat
Arslan,Ismail
Sahin,Ahmet Bilgehan
Güllülü,Mustafa
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ayar,Yavuz
Ersoy,Alparslan
Oksuz,Mustafa Ferhat
Ocakoglu,Gokhan
Vuruskan,Berna Aytac
Yildiz,Abdülmecit
Isiktas,Emel
Oruc,Aysegül
Celikci,Sedat
Arslan,Ismail
Sahin,Ahmet Bilgehan
Güllülü,Mustafa
dc.subject.por.fl_str_mv AA amyloidosis
Chronic kidney disease
Familial Mediterranean fever
Mortality
Renal survival
topic AA amyloidosis
Chronic kidney disease
Familial Mediterranean fever
Mortality
Renal survival
description Abstract Aim Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. Methods: A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Results: Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65 ± 3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p = 0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p = 0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p = 0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3 ± 16 months. Conclusion Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.
publishDate 2017
dc.date.none.fl_str_mv 2017-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600535
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600535
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.rbre.2017.02.002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Reumatologia
publisher.none.fl_str_mv Sociedade Brasileira de Reumatologia
dc.source.none.fl_str_mv Revista Brasileira de Reumatologia v.57 n.6 2017
reponame:Revista Brasileira de Reumatologia (Online)
instname:Sociedade Brasileira de Reumatologia (SBR)
instacron:SBR
instname_str Sociedade Brasileira de Reumatologia (SBR)
instacron_str SBR
institution SBR
reponame_str Revista Brasileira de Reumatologia (Online)
collection Revista Brasileira de Reumatologia (Online)
repository.name.fl_str_mv Revista Brasileira de Reumatologia (Online) - Sociedade Brasileira de Reumatologia (SBR)
repository.mail.fl_str_mv ||sbre@terra.com.br
_version_ 1750318051731963904